{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:56:05Z","timestamp":1791968165635,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jaci.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T13:47:55Z","timestamp":1501768075000},"page":"349-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":170,"title":["Mast cell activation syndromes"],"prefix":"10.1016","volume":"140","author":[{"given":"Cem","family":"Akin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.06.007_bib1","unstructured":"Available at: http:\/\/www.aaaai.org\/about-aaaai\/newsroom\/allergy-statistics. Accessed June 28, 2017."},{"key":"10.1016\/j.jaci.2017.06.007_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2017.06.007_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.06.007_bib4","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.06.007_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jaci.2005.01.009","article-title":"Symposium on the definition and management of anaphylaxis: summary report","volume":"115","author":"Sampson","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2017.06.007_bib9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4049\/jimmunol.1001806","article-title":"Processing of human protryptase in mast cells involves cathepsins L, B, and C","volume":"187","author":"Le","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.aller.2014.05.002","article-title":"Clinical characteristics and risk profile of patients with elevated baseline serum tryptase","volume":"42","author":"Fellinger","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2017.06.007_bib11","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2017.06.007_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40413-016-0094-3","article-title":"Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases","volume":"9","author":"Metcalfe","year":"2016","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2017.06.007_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.anai.2013.06.031","article-title":"Lipid mediators and allergic diseases","volume":"111","author":"Fanning","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.06.007_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaci.2017.06.007_bib16","doi-asserted-by":"crossref","first-page":"e0124912","DOI":"10.1371\/journal.pone.0124912","article-title":"Determination of plasma heparin level improves identification of systemic mast cell activation disease","volume":"10","author":"Vysniauskaite","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2017.06.007_bib17","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1074\/jbc.M111.325712","article-title":"Mast cell restricted mouse and human tryptase-heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen","volume":"287","author":"Prieto-Garc\u00eda","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2017.06.007_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2017.06.007_bib19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2017.06.007_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2003-08-2769","article-title":"NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation","volume":"104","author":"Tkaczyk","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.06.007_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/adc.86.5.315","article-title":"Paediatric mastocytosis","volume":"86","author":"Carter","year":"2002","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaci.2017.06.007_bib22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.06.007_bib23","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.06.007_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"\u00c1lvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","article-title":"A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients","volume":"38","author":"Doyle","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaci.2017.06.007_bib26","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.06.007_bib27","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2017.06.007_bib30","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040559","article-title":"Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity","volume":"40","author":"Galli","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib31","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI85538","article-title":"Different activation signals induce distinct mast cell degranulation strategies","volume":"126","author":"Gaudenzio","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.06.007_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/ACI.0000000000000377","article-title":"Pharmacotherapy of mast cell disorders","author":"G\u00fclen","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1081-1206(10)63100-6","article-title":"Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen","volume":"79","author":"Patterson","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib34","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib35","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2169\/internalmedicine.50.4640","article-title":"Omalizumab treatment of systemic mast cell activation disease: experiences from four cases","volume":"50","author":"Molderings","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.jaci.2017.06.007_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.06.007_bib38","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.06.007_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000204898","article-title":"Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon","volume":"85","author":"Pardini","year":"1991","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jaci.2017.06.007_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.06.007_bib41","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.06.007_bib42","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.06.007_bib43","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2017.06.007_bib44","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.06.007_bib45","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.06.007_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.03.013","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity","author":"Regan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/all.13166","article-title":"BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils","author":"Smiljkovic","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.007_bib48","doi-asserted-by":"crossref","first-page":"AB65","DOI":"10.1016\/j.jaci.2014.12.1146","article-title":"A new disease cluster: mast cell activation syndrome, postural orthostatic tachycardia syndrome, and Ehlers-Danlos syndrome","volume":"135","author":"Cheung","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.007_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajmg.c.31555","article-title":"Mast cell disorders in Ehlers-Danlos syndrome","volume":"175","author":"Seneviratne","year":"2017","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.jaci.2017.06.007_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000158259.68614.40","article-title":"Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders","volume":"45","author":"Shibao","year":"2005","journal-title":"Hypertension"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917310254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917310254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:03:59Z","timestamp":1758791039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917310254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0091674917310254"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.06.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727879039.793539107","asserted-by":"object"}]},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast cell activation syndromes","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}